Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
13/03/2023 | 11:16 | Edgar (US Regulatory) | Termination of Registration of a Class of Security Under Section 12(g) (15-12g) | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
10/03/2023 | 12:05 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
06/03/2023 | 20:02 | Edgar (US Regulatory) | Post-effective Amendment to Registration Statement (pos Am) | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
06/03/2023 | 19:17 | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
03/03/2023 | 15:27 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
27/02/2023 | 22:05 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
16/02/2023 | 23:14 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
07/02/2023 | 22:01 | GlobeNewswire Inc. | Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
06/02/2023 | 14:00 | GlobeNewswire Inc. | Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
19/01/2023 | 22:05 | GlobeNewswire Inc. | Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
04/01/2023 | 22:21 | Edgar (US Regulatory) | Proxy Statement - Merger or Acquisition (definitive) (defm14a) | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
21/12/2022 | 22:56 | Edgar (US Regulatory) | Proxy Statement - Merger or Acquisition (preliminary) (prem14a) | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
22/11/2022 | 22:01 | GlobeNewswire Inc. | Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
15/11/2022 | 12:10 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
14/11/2022 | 22:25 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
14/11/2022 | 10:26 | TipRanks | How Will Indivior’s $145M Purchase of Opiant Boost the Stock? | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
14/11/2022 | 08:13 | GlobeNewswire Inc. | Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
14/11/2022 | 08:12 | GlobeNewswire Inc. | Indivior PLC to Acquire Opiant Pharmaceuticals | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
14/11/2022 | 08:10 | PR Newswire (US) | Indivior To Acquire Opiant Pharmaceuticals | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
27/10/2022 | 22:05 | GlobeNewswire Inc. | Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022 | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
06/10/2022 | 14:01 | GlobeNewswire Inc. | Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
22/08/2022 | 22:05 | GlobeNewswire Inc. | Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndrome | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
12/08/2022 | 13:30 | PR Newswire (Canada) | MindMed Strengthens Board with Appointment of Two New Independent Directors | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
11/08/2022 | 22:05 | GlobeNewswire Inc. | Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
08/08/2022 | 22:05 | GlobeNewswire Inc. | Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefene | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
02/08/2022 | 22:05 | GlobeNewswire Inc. | Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent With Claims Covering OPNT003 for the Treatment of Opioid Overdose | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
01/08/2022 | 22:05 | GlobeNewswire Inc. | Opiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022 | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
28/06/2022 | 22:05 | GlobeNewswire Inc. | Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
17/06/2022 | 22:54 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |
08/06/2022 | 22:05 | GlobeNewswire Inc. | Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene | NASDAQ:OPNT | Opiant Pharmaceuticals Inc |